Are tumours angiogenesis-dependent?

Journal of Pathology

Volumn 202, Issue 1, 2004, Pages 5-13

  Verheul, H M W ^a   Voest, E E ^a   Schlingemann, R O ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; MONOCLONAL ANTIBODY LM 609; SEMAXANIB; TRASTUZUMAB; VANDETANIB; VATALANIB;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER RESEARCH; CARCINOGENICITY; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG CYTOTOXICITY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GROWTH REGULATION; HUMAN; MOUSE; NONHUMAN; ORGANOGENESIS; OXYGEN TRANSPORT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CAPILLARIES; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE;

EID: 0347916982     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1473     Document Type: Review

References (97)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
3. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999; 1: 293-302.
4. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875- 1887.
5. Abdalla SA, Behzad F, Bsharah S, et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 1999; 6: 839-842.
6. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998; 16: 118-123.
7. Kainz C, Speiser P, Wanner C, et al. Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res 1995; 15: 1549-1551.
8. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999; 125: 419-426.
9. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996; 167-190.
10. Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol 2000; 35: 227-231.
11. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
12. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
13. Schlingemann RO, Rietveld FJ, de Waal RM, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990; 62: 690-696.
14. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990; 136: 1393-1405.
15. Warren BA. The ultrastructure of the microcirculation at the advancing edge of Walker 256 carcinoma. Microvasc Res 1970; 2: 443-453.
16. Hammersen F, Endrich B, Messmer K. The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. Int J Microcirc Clin Exp 1985; 4: 31-43.
17. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160: 985-1000.
18. Tannock IF. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 1970; 30: 2470-2476.
19. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45: 136-139.
20. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-276.
21. Ausprunk DH, Knighton DR, Folkman J. Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and pre-existing graft blood vessels. Am J Pathol 1975; 79: 597-628.
22. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65.
23. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
24. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
25. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-6628.
26. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
27. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
28. Hamby JM, Showalter HD. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82: 169-193.
29. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-2539.
30. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
31. Schlingemann RO, Oosterwijk E, Wesseling P, Rietveld FJ, Ruiter DJ. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 1996; 179: 436-442.
32. Tucker GC. Inhibitors of integrins. Curr Opin Pharmacol 2002; 2: 394-402.
33. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000; 36: 1695-1705.
34. Lwaleed BA, Bass PS, Cooper AJ. The biology and tumour-related properties of monocyte tissue factor. J Pathol 2001; 193: 3-12.
35. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-2190.
36. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
37. Hladovec J. The effect of some platelet aggregating and potential thrombosis-promoting substances on the development of experimental arterial thrombosis. Thromb Diath Haemorrh 1973; 29: 196-200.
38. George F, Brisson C, Poncelet P, et al. Rapid isolation of human endothelial cells from whole blood using S-Endol monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992; 67: 147-153.
39. Sbarbati R, de Boer M, Marzilli M, Scarlattini M, Rossi G, van Mourik JA. Immunologic detection of endothelial cells in human whole blood. Blood 1991; 77: 764-769.
40. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-1590.
41. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661.
42. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
43. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
44. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
45. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361-1370.
46. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
47. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000; 113(Pt 22): 3897-3905.
48. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999; 401: 670-677.
49. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7: 1194-1201.
50. Volpert OV, Pili R, Sikder HA, et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2002; 2: 473-483.
51. Kuzu I, Bicknell R, Fletcher CD, Gatter KC. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab Invest 1993; 69: 322-328.
52. Regezi JA, Macphail LA, Richards DW, Greenspan JS. A study of macrophages, macrophage-related cells, and endothelial adhesion molecules in recurrent aphthous ulcers in HIV-positive patients. J Dent Res 1993; 72: 1549-1553.
53. Shi Q, Le X, Wang B, et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001; 20: 3751-3756.
54. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182-193.
55. Beerepoot LV, Shima DT, Kuroki M, Yeo KT, Voest EE. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res 1996; 56: 3747-3751.
56. Satake S, Kuzuya M, Miura H, et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Cell 1998; 90: 161-168.
57. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
58. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-1603.
59. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-812.
60. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 1526-1528.
61. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002; 62: 1931-1934.
62. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-1381.
63. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: Support for the concept of tumor dormancy. J Natl Cancer Inst 1994; 86: 45-48.
64. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996; 41: 177-185.
65. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998; 184: 119-122.
66. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566-1577.
67. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-147.
68. Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
69. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440-450.
70. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94: 4143-4155.
71. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
72. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
73. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19: 45S-51S.
74. Verheul HM, Pinedo HM. Anti-angiogenic drugs: implications of anti-angiogenic drug discovery. Updates, Principles & Practice of Oncology, vol 16. Lippincott, Williams & Wilkins: Philadelphia, 2002; 1-15.
75. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-1667.
76. Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 2002; 50: 767-777.
77. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001; 7: 3366-3374.
78. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002; 2: 727-739.
79. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
80. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002; 37: 17-27.
81. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280.
82. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 2001; 28: 93-105.
83. Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int J Oncol 2002; 21: 469-475.
84. Stoppler H, Malerczyk C, Block K, Aigner A, Czubayko F. The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene 2001; 20: 7430-7436.
85. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44.
86. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
87. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-866.
88. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090-5101.
89. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 2000; 6: 4422-4431.
90. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213.
91. Rak J, Mitsuhashi Y, Bayko, L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
92. Slack JL, Bornstein P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ 1994; 5: 1373-1380.
93. Bein K, Ware JA, Simons M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem 1998; 273: 21423-21429.
94. Sheibani N, Frazier WA. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett 1996; 107: 45-52.
95. Claudio PP, Stiegler P, Howard CM, et al. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res 2001; 61: 462-468.
96. McGregor LM, McCune BK, Graff JR, et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci U S A 1999; 96: 4540-4545.
97. Leung SK, Ohh M. Playing tag with HIF: the VHL story. J Biomed Biotechnol 2002; 2: 131-135.